Active Stocks in List: Assured Guaranty (NYSE:AGO), Chicago Bridge & Iron (NYSE:CBI), Oracle (NYSE:ORCL), Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
Assured Guaranty (AGO) (Europe) and an affiliate announcesd that it will guarantee a GBP77 mln wrapped bond, issued by Solutions 4 North Tyneside (Finance) to finance the development and refurbishment of homes for older people in the North Tyneside area. The publicly listed bond priced on 24th March 2014 at 5.259%.
Assured Guaranty Ltd. (NYSE:AGO) [Trend Analysis] reported the decrease of -0.39% and closed at $25.79 with the total traded volume of 1.15 million shares. Its market capitalization is $4.71 billion. The company’s shares have gained 9.05% in the last one month and 9.59% in the previous three months, compared to an increase of 1.11% and 1.76% in the S&P 500 during the respective periods.
Get Free Inside Facts on (NYSE:AGO)
CB&I (CBI) reported that it has been awarded a contract by Shandong Sincier Petrochemical for the license and engineering design of a grassroots propane and butane dehydrogenation unit to be built in Dongying, Shandong Province, China.
Chicago Bridge & Iron Company N.V. (NYSE:CBI) [Trend Analysis] gained 0.40%, closing the day at $85.69 in last regular trading. Corporation has the total of cash of $420.50 million as compares to total debt of $1.84 billion for the most recent quarter with the current ratio of 0.71 for the most recent quarter.
Acts and Reacts in Analytic Report, Finds (NYSE:CBI)
Oracle (ORCL) reported that Java 8 and Oracle Health Sciences Empirica Healthcare Analysis release. As part of the most significant Java technology release by Oracle, the company will host the Java 8 launch webcast today (13:00 ET). Oracle is releasing Java Platform, Standard Edition 8 (Java SE 8), Java Platform, Micro Edition 8 (Java ME 8) and the related releases of Oracle’s Java Embedded products.
In last trading session, shares of Oracle Corporation (NYSE:ORCL) [Trend Analysis] surged 0.58%, closing the day at $38.40, after wavering among $38.10 and $38.50 during the trading session. Its net profit margin in lasted declared quarter was 27.56% as compared to 29.38% in previous year in same year. Its beta value stands at 1.28 times.
What are Prospects of ORCL, Find the Free Technical Analysis
Catalyst Pharmaceutical Partners, Inc. (CPRX) reported that, at a newly held meeting, the independent Data Monitoring Committee (:DMC) overseeing the firm’s ongoing pivotal Phase 3 clinical trial evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) recommended that the trial be continued as planned based on the committee’s review of safety and clinical data from the trial. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) [Trend Analysis] after opening at $2.35 hit its intraday high price of $2.48 moreover then finished at $2.36 by shares raised 3.51%.
Moving Forces Behind (NASDAQ:CPRX) On Confident Run! Click Here
This content does not and shall not represent an offer to sell or the solicitation of an offer to buy any of the company’s stocks or securities. As well nor shall there be any sale of the company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or jurisdiction. Read Full Disclaimer Here